| pubmed-article:9707374 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9707374 | lifeskim:mentions | umls-concept:C0042769 | lld:lifeskim |
| pubmed-article:9707374 | lifeskim:mentions | umls-concept:C0029347 | lld:lifeskim |
| pubmed-article:9707374 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:9707374 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:9707374 | lifeskim:mentions | umls-concept:C0123759 | lld:lifeskim |
| pubmed-article:9707374 | lifeskim:mentions | umls-concept:C2004454 | lld:lifeskim |
| pubmed-article:9707374 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:9707374 | lifeskim:mentions | umls-concept:C1423842 | lld:lifeskim |
| pubmed-article:9707374 | lifeskim:mentions | umls-concept:C0205421 | lld:lifeskim |
| pubmed-article:9707374 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:9707374 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9707374 | pubmed:dateCreated | 1998-10-16 | lld:pubmed |
| pubmed-article:9707374 | pubmed:abstractText | Interleukin 12 (IL-12) directs the differentiation of undifferentiated T helper (Th0) cells to T helper type 1 (Th1) cells and induces a cell-mediated immune response. To evaluate the effect of IL-12 on the course of influenza A virus infection, BALB/c mice were administered a daily intraperitoneal dose of 1000 ng of IL-12 or saline on days -1 to +4 for a total of six treatments. The treatment generally enhanced Th1-mediated responses. IFNgamma lung concentrations were 1193 +/- 275 pg/100 microl in controls and 3693 +/- 745 pg/100 microl in IL-12-treated mice at day 5. IFNgamma levels were undetectable at day 13 in controls and 1335 +/- 220 pg/100 microl in IL-12-treated mice. Cytokine production was also assessed at the single-cell level for mediastinal lymph nodes. IL-12 treatment increased the number of IL-2- and IFNgamma-producing cells and decreased the number of IL-4- and IL-10-producing cells. IL-12 treatment decreased the anti-influenza antibody response, especially anti-influenza IgG1 antibody resulting in an increased IgG2a/IgG1 ratio. Primary pulmonary CTL activity on day 5 was low for both groups (10% specific lysis). Secondary CTL activity at day 11 was higher for control mice than for IL-12-treated mice on day 11 (44 versus 34%), but not on day 13. Despite this overall enhancement of Th1-mediated immune functions, the IL-12 treatment increased severity of the disease. Following infection, control and IL-12-treated mice decreased their body weight to approximately 75% of their initial weight. After day 5, the control mice started to recover, while IL-12-treated mice did not begin recovering until day 9. Pulmonary viral titers were 1.6 +/- 0.3 TCID50 in controls at day 5 compared to 2.4 +/- 0.3 for IL-12-treated mice (P < 0.01). In addition, control mice had significantly less severe inflammation and damage on histologic examination. Serum TNFalpha concentrations, undetectable in control mice, were elevated by IL-12 treatment up to 80 pg/ml at day 5 and decreased to zero at day 13. It is concluded that IL-12 administration to influenza-infected mice induces a switch from a Th2- to a Th1-mediated response, but inhibits recovery probably through induction of TNFalpha. | lld:pubmed |
| pubmed-article:9707374 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9707374 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9707374 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9707374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9707374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9707374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9707374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9707374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9707374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9707374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9707374 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9707374 | pubmed:month | May | lld:pubmed |
| pubmed-article:9707374 | pubmed:issn | 0166-3542 | lld:pubmed |
| pubmed-article:9707374 | pubmed:author | pubmed-author:FuxJ PJP | lld:pubmed |
| pubmed-article:9707374 | pubmed:author | pubmed-author:SmallP APAJr | lld:pubmed |
| pubmed-article:9707374 | pubmed:author | pubmed-author:ZanderDD | lld:pubmed |
| pubmed-article:9707374 | pubmed:author | pubmed-author:BenderB SBS | lld:pubmed |
| pubmed-article:9707374 | pubmed:author | pubmed-author:TaylorS FSF | lld:pubmed |
| pubmed-article:9707374 | pubmed:author | pubmed-author:CotteyRR | lld:pubmed |
| pubmed-article:9707374 | pubmed:author | pubmed-author:KostenseSS | lld:pubmed |
| pubmed-article:9707374 | pubmed:author | pubmed-author:HarmelingSS | lld:pubmed |
| pubmed-article:9707374 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9707374 | pubmed:volume | 38 | lld:pubmed |
| pubmed-article:9707374 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9707374 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9707374 | pubmed:pagination | 117-30 | lld:pubmed |
| pubmed-article:9707374 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:meshHeading | pubmed-meshheading:9707374-... | lld:pubmed |
| pubmed-article:9707374 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9707374 | pubmed:articleTitle | Interleukin 12 administration enhances Th1 activity but delays recovery from influenza A virus infection in mice. | lld:pubmed |
| pubmed-article:9707374 | pubmed:affiliation | Department of Pathology and Laboratory Medicine, University of Florida College of Medicine, Gainesville 32610-0275, USA. | lld:pubmed |
| pubmed-article:9707374 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9707374 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9707374 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9707374 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9707374 | lld:pubmed |
